13F Holdings
中文EN

SNDL SNDL Inc. IFRS Annual reports only

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1766600 · Reporting currency CAD · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY2.8%
TTM net income YoY83.4%
TTM EPS YoY83.3%
Revenue 3-yr CAGR9.9%
Net income 3-yr CAGR—

Margins

Gross margin27.3%
Operating margin-0.7%
Net margin-1.7%
FCF margin6.1%
EBITDA margin4.8%

Returns

ROE-1.4%
ROA-1.2%
ROIC (approx.)-0.6%
Asset turnover0.70x

Leverage & solvency

Liabilities / assets17.6%
Debt / equity0.00x
Current ratio4.88x
Interest coverage-0.95x

Cash quality & payout

Operating cash flow / net income-4.50x
Accruals ratio-6.5%
Payout ratio—
Capex / revenue1.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: CAD FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue946.40M920.45M909.01M712.20M56.13M
Cost of revenue687.75M680.12M718.59M——
Gross profit258.65M240.33M190.41M140.38M-9.00M
R&D expense489,000346,000324,0002.45M2.45M
SG&A expense182.16M187.24M199.72M140.17M38.04M
Operating income-6.35M-103.81M-163.17M-347.77M-134.38M
Interest expense6.69M7.16M11.36M178,00040,000
Pretax income-15.77M-105.61M-172.02M-379.77M-234.70M
Net income-15.77M-94.80M-172.66M-335.11M-226.98M
EBITDA45.60M-49.56M-102.95M-306.83M-129.09M
EPS (basic)-0.06-0.36-0.67-1.46—
EPS (diluted)-0.06-0.36-0.67-1.46—
Balance sheet
Cash & equivalents252.24M218.36M195.04M279.59M558.25M
Short-term investments484,00027.56M3.40M6.55M3.06M
Receivables24.10M24.55M20.85M17.56M10.87M
Inventory126.88M127.92M129.06M127.78M29.50M
Current assets449.62M461.84M406.91M501.48M728.17M
PP&E, netmay include right-of-use assets (IFRS)151.90M145.81M152.92M143.41M56.47M
Goodwill124.25M124.25M119.28M67.26M72.50M
Intangibles58.52M61.33M73.15M74.89M50.15M
Total assets1.34B1.35B1.47B1.56B1.43B
Current liabilities92.21M90.56M103.15M89.36M65.85M
Total liabilities234.72M215.89M243.82M231.69M98.13M
Shareholders' equity1.10B1.13B1.21B1.31B1.33B
Cash flow statement
Operating cash flow70.92M54.91M-16.65M-6.71M-155.75M
Capital expenditure12.81M8.62M7.84M10.67M3.79M
Free cash flow58.11M46.30M-24.49M-17.38M-159.54M
Investing cash flow17.45M17.76M-24.82M-230.16M-496.28M
Financing cash flow-54.49M-49.36M-43.08M-41.79M1.15B
Depreciation & amortization51.95M54.25M60.22M40.95M5.29M
Stock-based compensation13.90M20.04M15.40M9.67M12.31M
Share buybacks15.35M13.22M1.54M13.39M0

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.